Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study
单位：[1]Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China浙江大学医学院附属第一医院[2]Tongji Hosp, Wuhan, Hubei, Peoples R China华中科技大学同济医学院附属同济医院[3]Northern Jiangsu Peoples Hosp, Yangzhou, Jiangsu, Peoples R China[4]Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Heilongjiang, Peoples R China[5]Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China[6]BeiGene Beijing Co Ltd, Beijing, Peoples R China[7]307th Hosp Chinese Peoples Liberat Army, Beijing, Peoples R China
Xu Nong,Yuan Xianglin,Wang Buhai,et al.Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(4):doi:10.1200/JCO.2019.37.4_suppl.14.
APA：
Xu, Nong,Yuan, Xianglin,Wang, Buhai,Bai, Yu-Xian,Li, En Xiao...&Xu, Jianming.(2019).Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study.JOURNAL OF CLINICAL ONCOLOGY,37,(4)
MLA：
Xu, Nong,et al."Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study".JOURNAL OF CLINICAL ONCOLOGY 37..4(2019)
医学